The Novavax-Indian Serum Institute is asking the WHO for emergency vaccine approval
Novavax and the Indian Serum Institute Submit documents to the World Health Organization approving the use of COVID-19 Hybrid nanoparticles based on Novavax proteins are an emergency.
September 27, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company that develops and markets a newShaolingeneration vaccine for serious infectious diseases. The Indian Serum Institute (SII), together with its partners, has announced that it has been submitted to the World Health Organization (WHO) for approval of a vaccine against COVID-19. Protein-based hybrid nanoparticles with the Novavax Matrix-M imun Emergency Immunomodulator (EUL).
This WHO submission follows on from the fact that both parties had previously submitted documents to the Ministry of Drug Control in India (DCGI).
"Submission of WHO documents for approval of the use of COVID-19." Protein-Based Types In Need This is a significant step forward in accelerating access to and promoting the equitable distribution of vaccines to countries that need vaccines around the world, r1;said Stanley C. Erck, President and CEO of Novavax.
"This is another major breakthrough in the transformation of Novavax into a global commercial vaccine company." It also reinforces the value of global cooperation and the need for a diverse approach to help manage the epidemic. "
WHO's EUL approval will allow companies to export vaccines to countries at the COVAX facility, which is designed to distribute vaccines evenly and distributed to countries. Last month, SII and Novavax met all eligibility requirements for regulators in India, Indonesia and the Philippines.
start thinking about society's vaccines From pre-clinical, clinical research data to chemical, manufacturing and control data.
Edytowane przez pandara55 dnia 29-09-2021 12:14
Portal
